12:00 AM
 | 
May 17, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CD40 Ligand: Phase I data; Phase II

Data from 27 patients showed that the compound was safe and an optimum dose was obtained.

(Clinical...

Read the full 66 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >